Vici Health Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vici Health Sciences operates as a specialized service provider and CDMO, offering integrated R&D and manufacturing solutions to accelerate drug development for small pharmaceutical clients. The company leverages its formulation and regulatory expertise to guide products from early development through clinical trials and regulatory submission, with a track record in over 50 formulations and 30+ clinical trials. Positioned as a 'full-service CDMO partner,' Vici aims to de-risk and streamline the development pathway for its clients, particularly in complex areas like bioavailability enhancement and regulatory filings.

OncologyRare Disease

Technology Platform

Integrated pharmaceutical development services platform encompassing formulation science (including bioavailability enhancement), analytical method development/validation, cGMP clinical manufacturing, and regulatory strategy expertise, particularly for the 505(b)(2) and ANDA pathways.

Opportunities

The growing trend of outsourcing by small, virtual biopharma companies creates a large and expanding client base.

Specialization in complex regulatory pathways like 505(b)(2) offers a high-value niche for developing improved formulations and repurposed drugs, particularly in oncology and rare diseases.

Risk Factors

Revenue is highly dependent on the funding and success of small biotech clients, creating volatility.

The company faces intense competition from larger, established CDMOs and consulting firms.

Operational missteps in formulation or regulatory filings could severely damage its reputation.

Competitive Landscape

Vici competes in the fragmented CDMO and pharma consulting market against large global CDMOs (e.g., Lonza, Catalent), specialized formulation developers, and regulatory consulting firms. Its differentiation lies in positioning as an integrated, end-to-end partner specifically for small pharma, with claimed expertise in the complex 505(b)(2) niche.

More companies in United States →